Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 1.00 |
| ▸ | TTR | P02766 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.57 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.56 |
| ▸ | BAX | Q07812 | 1/20 | 0.56 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL510065 | 1.00 | LTA4H (1.00) | LTA4HTTRTSHRFFAR1NR1H2 | |
| SCHEMBL28009008 | 0.98 | LTA4H (0.95) | LTA4HTTRTSHRFFAR1NR1H2 | |
| SCHEMBL28009007 | 0.98 | LTA4H (0.95) | LTA4HTTRTSHRFFAR1NR1H2 | |
| Diphenylether SCHEMBL27843672 | 0.93 | LTA4H (0.86) | LTA4HTTRTSHRFFAR1NR1H2 | |
| SCHEMBL15831788 | 0.92 | LTA4H (0.84) | LTA4HTTRTSHRFFAR1NR1H2 | |
| Diphenylether SCHEMBL27875947 | 0.91 | LTA4H (0.83) | LTA4HTTRTSHRFFAR1NR1H2 | |
| SCHEMBL5342317 | 0.90 | LTA4H (0.81) | LTA4HTTRTSHRFFAR1SRD5A2 | |
| SCHEMBL21993468 | 0.89 | LTA4H (0.80) | LTA4HTTRTSHRFFAR1NR1H2 | |
| SCHEMBL1745252 | 0.89 | LTA4H (0.80) | LTA4HTTRTSHRFFAR1NR1H2 | |
| SCHEMBL14173664 | 0.88 | LTA4H (0.78) | LTA4HTTRTSHRFFAR1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1400599-B1 | Mass label linked hybridisation probes | XZILLION GMBH & CO KG (DE) | 2007-10-03 | — | — | EP | disclosed |
| EP-0979305-B1 | MASS LABEL LINKED HYBRIDISATION PROBES | XZILLION GMBH & CO KG (DE) | 2006-09-27 | — | — | EP | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
| US-20050042625-A1 | Mass label linked hybridisation probes | XZILLION GMBH & CO. (DE) | 2005-02-24 | — | — | US | disclosed |
| EP-1400599-A1 | Mass label linked hybridisation probes | Xzillion GmbH & CO.KG (DE) | 2004-03-24 | — | — | EP | disclosed |
| US-6699668-B1 | FOR DETERMINING HYBRIDIZATION BY CLEAVING THE LABEL FROM THE HYBRIDIZED PROBE, WHERE EACH MASS LABEL IS RELATABLE TO THE PROBE'S BASE SEQUENCE BY MASS SPECTROMETRY | XZILLION GMBH & CO. (DE) | 2004-03-02 | — | — | US | disclosed |
| EP-1095052-A1 | SILICON-CONTAINING LINKERS FOR NUCLEIC ACID MASS MARKERS | Brax Group Limited (GB) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000002894-A1 | SILICON-CONTAINING LINKERS FOR NUCLEIC ACID MASS MARKERS | BRAX GROUP LIMITED (GB) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012093-A1 | Receptor Function Regulator | GPR119, GIPR, INSR | LTA4H 1978/4885TTR 4688/4885TSHR 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.